Brokerages Set Zoetis Inc. (NYSE:ZTS) Price Target at $151.75

Zoetis Inc. (NYSE:ZTS) has been assigned an average recommendation of “Hold” from the fifteen research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $141.25.

ZTS has been the topic of several research reports. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. JPMorgan Chase & Co. dropped their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday. Stifel Nicolaus set a $105.00 price target on shares of Zoetis in a research report on Friday. BTIG Research reiterated a “buy” rating and issued a $160.00 price target on shares of Zoetis in a research report on Thursday, February 26th. Finally, Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: JPMorgan lowered its price target on Zoetis from $190 to $130, but kept an overweight rating, implying the stock still has meaningful upside from current levels. Benzinga report on JPMorgan target cut
• Neutral Sentiment: Some analysts remain constructive overall, with recent coverage still showing buy/overweight views and price targets well above the current share price, suggesting longer-term confidence despite near-term pressure.
• Negative Sentiment: Zoetis missed Q1 earnings and revenue estimates, which immediately hurt sentiment around the stock.
• Negative Sentiment: The company cut its FY2026 guidance after seeing weaker U.S. companion animal demand and pricing pressure, raising concerns that pet owners are spending less on veterinary care and premium products. Benzinga report on weak pet care demand
• Negative Sentiment: Media coverage described the earnings release as a sharp disappointment, with reports highlighting a steep selloff after investors reacted to the softer outlook.
• Negative Sentiment: Ademi LLP announced a securities fraud investigation into Zoetis, adding another overhang for shares as investors assess potential legal risk.

Zoetis Stock Performance

ZTS stock opened at $82.80 on Monday. The company has a market capitalization of $34.71 billion, a P/E ratio of 13.73, a PEG ratio of 1.29 and a beta of 0.87. The company has a 50-day simple moving average of $118.49 and a 200 day simple moving average of $123.70. Zoetis has a fifty-two week low of $81.10 and a fifty-two week high of $172.23. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Sell-side analysts predict that Zoetis will post 6.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zoetis

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Summit Place Financial Advisors LLC raised its position in Zoetis by 0.4% in the third quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock worth $2,834,000 after acquiring an additional 76 shares in the last quarter. CWA Asset Management Group LLC raised its holdings in Zoetis by 1.1% during the 3rd quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company’s stock worth $1,059,000 after buying an additional 80 shares during the period. RFG Advisory LLC raised its holdings in Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after buying an additional 80 shares during the period. YANKCOM Partnership raised its holdings in Zoetis by 3.5% during the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after buying an additional 81 shares during the period. Finally, Evergreen Capital Management LLC raised its holdings in Zoetis by 3.3% during the 3rd quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock worth $394,000 after buying an additional 85 shares during the period. 92.80% of the stock is currently owned by institutional investors.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.